Mo, Mai 27th 2024
Roche welcomes Boris Zaïtra as new Head of Corporate Business Development, enhancing Pharma and Group operations.
Roche will see a significant change in its Group Executive Committee on July 1. The current Head of Pharma Partnering, James Sabry, will retire, with Boris Zaïtra taking over the role. Zaïtra, presently Head of Group Business Development, will be appointed as the Head of Corporate Business Development. This new role will merge the functions of Pharma Partnering and Group Business Development, as stated in Roche’s Monday announcement. Zaïtra has been with Roche since 2012, starting his journey in Basel.
James Sabry, who joined Roche in 2010 as Head of Genentech Partnering, was appointed Head of Pharma Partnering in 2018. Roche CEO Thomas Schinecker praised Sabry for his pivotal role in crucial pharma transactions that led to the launch of numerous new medicines.
Additionally, Roche has extended its collaboration with Hitachi High-Tech for another decade. This partnership, which began in 1978, has led to significant innovations in in-vitro diagnostics solutions.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic 
